Literature DB >> 8884161

A comparative review of the adverse effects of calcium antagonists.

H T Dougall1, J McLay.   

Abstract

A large number of drugs within the 3 currently classes of calcium antagonists are in common medical use for the treatment of hypertension and ischaemic heart disease. The reported adverse effect profile for each of these drugs varies, but tends to hold true to drug class and are typified by the adverse reactions reported for nifedipine and amlodipine (dihydropyridines), diltiazem (benzothiazepines) and verapamil (phenylalkylamines). Minor adverse effects such as flushing, headache, ankle oedema, palpitations and constipation are not uncommon and frequently require the cessation of treatment. Of greater concern affecting the wide and common first-line use of calcium antagonists is the as-yet unresolved issue of a reportedly greater risk of myocardial infarction and death following the use of short-acting nifedipine in patients with a history of hypertension, myocardial infarction or angina. Until this issue is fully resolved, it would seem prudent to limit the use of this agent in 'at-risk' patients and to await the results of further prospective studies before a final conclusion can be made.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8884161     DOI: 10.2165/00002018-199615020-00002

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  156 in total

1.  Diltiazem-induced granulomatous hepatitis.

Authors:  E Toft; M Vyberg; K Therkelsen
Journal:  Histopathology       Date:  1991-05       Impact factor: 5.087

2.  The effects of intravenous and oral nifedipine on ex vivo platelet function.

Authors:  T J Walley; K L Woods; D B Barnett
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

3.  [Nicardipine may have an adverse effect on the blood sugar equilibrium of non-insulin-dependent diabetics].

Authors:  I Belleville; G Vaillant; M Farnier; J M Brun
Journal:  Presse Med       Date:  1987-10-24       Impact factor: 1.228

4.  Lymphatic contractions.

Authors:  W L Olszewski; A Engeset
Journal:  N Engl J Med       Date:  1979-02-08       Impact factor: 91.245

5.  Impotence during therapy with verapamil.

Authors:  B D King; R Pitchon; E H Stern; P Schweitzer; R R Schneider; I Weiner
Journal:  Arch Intern Med       Date:  1983-06

6.  Hepatotoxicity due to treatment with verapamil.

Authors:  S J Brodsky; S S Cutler; D A Weiner; M D Klein
Journal:  Ann Intern Med       Date:  1981-04       Impact factor: 25.391

7.  Dihydropyridine calcium antagonists and the trough: peak ratio: focus on adverse effects.

Authors:  M G Myers
Journal:  J Hypertens Suppl       Date:  1994-11

8.  Incidence of verapamil-induced gingival hyperplasia in a dental population.

Authors:  C S Miller; D D Damm
Journal:  J Periodontol       Date:  1992-05       Impact factor: 6.993

9.  Gingival hyperplasia: a side effect of nifedipine and diltiazem.

Authors:  L Fattore; M Stablein; G Bredfeldt; T Semla; M Moran; J M Doherty-Greenberg
Journal:  Spec Care Dentist       Date:  1991 May-Jun

10.  The risk of myocardial infarction associated with antihypertensive drug therapies.

Authors:  B M Psaty; S R Heckbert; T D Koepsell; D S Siscovick; T E Raghunathan; N S Weiss; F R Rosendaal; R N Lemaitre; N L Smith; P W Wahl
Journal:  JAMA       Date:  1995 Aug 23-30       Impact factor: 56.272

View more
  12 in total

Review 1.  Tolerability of Antihypertensive Medications in Older Adults.

Authors:  Thiruvinvamalai S Dharmarajan; Lekshmi Dharmarajan
Journal:  Drugs Aging       Date:  2015-10       Impact factor: 3.923

Review 2.  Bioequivalence of controlled-release calcium antagonists.

Authors:  R Schall; F R Müller; F O Müller; H G Luus
Journal:  Clin Pharmacokinet       Date:  1997-01       Impact factor: 6.447

Review 3.  The classification of calcium antagonists and their selection in the treatment of hypertension. A reappraisal.

Authors:  T F Lüscher; F Cosentino
Journal:  Drugs       Date:  1998-04       Impact factor: 9.546

Review 4.  Trimetazidine. A review of its use in stable angina pectoris and other coronary conditions.

Authors:  K J McClellan; G L Plosker
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

Review 5.  A review of calcium channel antagonists in the treatment of pediatric hypertension.

Authors:  Shobha Sahney
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 6.  Drug interactions with angiotensin receptor blockers: a comparison with other antihypertensives.

Authors:  Thomas Unger; Elena Kaschina
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 7.  Drug treatment of stable angina pectoris in the elderly: defining the place of calcium channel antagonists.

Authors:  Sanjay Kumar; Roger J C Hall
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

8.  Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects.

Authors:  C Kollmannsberger; D Soulieres; R Wong; A Scalera; R Gaspo; G Bjarnason
Journal:  Can Urol Assoc J       Date:  2007-06       Impact factor: 1.862

Review 9.  Calcium channel blocker-induced gingival enlargement.

Authors:  R Livada; J Shiloah
Journal:  J Hum Hypertens       Date:  2013-06-06       Impact factor: 3.012

Review 10.  Cluster headache pathophysiology - insights from current and emerging treatments.

Authors:  Diana Y Wei; Peter J Goadsby
Journal:  Nat Rev Neurol       Date:  2021-03-29       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.